A PHASE I TRIAL OF DAILY 5- AZA 2'DEOXYCYTIDINE (DAC) AND SODIUM PHENYLBUTYRA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项确定地西他滨与低剂量苯丁酸钠联合给药的MTD的I期研究。 将在该组合中评估毒性。 药效学活性将通过评价外周白色血细胞中的乙酰化组蛋白和外周血中血红蛋白F的表达来定义。 将在唾液和口腔细胞中评价DNA变化。 将在第1周期苯丁酸钠给药后第15天进行药代动力学研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I study to determine the MTD of Decitabine given in combination with low doses of Sodium Phenylbutyrate. Toxicities will be assessed in this combination. Pharmacodynamic activity will be defined by the evaluation of acetylated histones in peripheral white blood cells and the expression of hemoglobin F in peripheral blood. DNA changes will be evaluated in saliva and buccal cells. Pharmacokinetics will be done on cycle 1, day 15 after administration of Sodium Phenylbutyrate.